SCHEMBL211017

SCHEMBL211017

CCC(=O)c1cccc([N+](=O)[O-])c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.67
CES2 O00748 1/20 0.66
CES1 P23141 1/20 0.66
TP53 P04637 1/20 0.64
CYP1A2 P05177 1/20 0.62
CYP3A4 P08684 1/20 0.62
CYP2C9 P11712 1/20 0.62
TSHR P16473 2/20 0.62
KMO O15229 1/20 0.60
KMT2A Q03164 3/20 0.57
SMN1; SMN2 Q16637 2/20 0.57
GAA P10253 1/20 0.56
MEN1 O00255 2/20 0.55
PRSS1 P07477 1/20 0.54
PRSS2 P07478 1/20 0.54
PRSS3 P35030 1/20 0.54
MAPT P10636 2/20 0.54
HTT P42858 2/20 0.54
RAB9A P51151 1/20 0.54
MITF O75030 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL568615 0.87 ALDH1A1 (0.63) ALDH1A1CES2CES1TP53CYP1A2
SCHEMBL28341610 0.86 ALDH1A1 (0.67) ALDH1A1CES2CES1TP53CYP1A2
SCHEMBL1986403 0.86 CES2 (0.70) ALDH1A1CES2CES1TP53TSHR
SCHEMBL312393 0.84 CES2 (0.68) ALDH1A1CES2CES1TP53TSHR
SCHEMBL30512072 0.84 CES2 (0.68) ALDH1A1CES2CES1TP53TSHR
SCHEMBL27570821 0.83 ALDH1A1 (0.68) ALDH1A1CES2CES1TP53TSHR
SCHEMBL13785092 0.83 ALDH1A1 (0.63) ALDH1A1CES2CES1TP53TSHR
SCHEMBL38656427 0.83 ALDH1A1 (0.68) ALDH1A1CES2CES1TP53TSHR
SCHEMBL8921654 0.83 ALDH1A1 (0.68) ALDH1A1CES2CES1TP53TSHR
SCHEMBL5016737 0.83 ALDH1A1 (0.58) ALDH1A1CES2CES1TP53TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 237 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112724957-B Preparation method of high-temperature-resistant composite cross-linking agent 东营市宝泽能源科技有限公司 2021-06-18 CN claimed
CN-112724957-A Preparation method of high-temperature-resistant composite cross-linking agent 东营市宝泽能源科技有限公司 2021-04-30 CN claimed
CN-109390156-B One kind disappears hydrogen agent and preparation method thereof, aluminum electrolytic capacitor electrolyte 惠州市宙邦化工有限公司 2019-11-15 CN claimed
CN-109390156-A One kind disappears hydrogen agent and preparation method thereof, aluminum electrolytic capacitor electrolyte 惠州市宙邦化工有限公司 2019-02-26 CN claimed
US-20150237857-A1 ANTIBACTERIAL INHIBITORS MCMASTER UNIVERSITY (CA) 2015-08-27 US claimed
EP-2882430-A1 ANTIBACTERIAL INHIBITORS McMaster University (CA) 2015-06-17 EP claimed
CN-102516196-B Alpha, beta-unsaturated ketone compound containing thiazole heterocycle, its preparation method and application UNIV SHANDONG 2014-09-03 CN claimed
WO-2014022923-A1 ANTIBACTERIAL INHIBITORS MCMASTER UNIVERSITY (CA) 2014-02-13 WO claimed
CN-1681470-A Agent for dyeing keratinous fibres HENKEL KGAA (DE) 2005-10-12 CN claimed
WO-2004052883-A2 PROCESS FOR THE SEPARATION OF ENANTIOMERS HONEYWELL INTERNATIONAL INC. (US) 2004-06-24 WO claimed
US-20040110957-A1 Process for the synthesis of an antiviral compound HONEYWELL INTERNATIONAL, INC. (US) 2004-06-10 US claimed
CN-111118076-B Method for biocatalytically reducing nitro compound 重庆博腾制药科技股份有限公司 2024-03-08 CN disclosed
WO-2023115621-A1 METHOD FOR PREPARING Α-HALOGENATED ACETOPHENONE COMPOUND UNDER CATALYSIS OF IONIC LIQUID [TEA][TFOH]2 大连大学 2023-06-29 WO disclosed
WO-2023101326-A1 NOVEL COMPOUND AS AUTOTAXIN INHIBITOR AND USE THEREOF 주식회사 넥스트젠바이오사이언스 2023-06-08 WO disclosed
WO-2021226327-A1 NUCLEOTIDE CLEAVABLE LINKERS WITH RIGID SPACERS AND USES THEREOF Singular Genomics Systems, Inc. (US) 2021-11-11 WO disclosed
EP-0163854-A2 Process for the elimination of fluorescence and cationic or amphoteric aromatic nitro compounds BAYER AG (DE) 1985-12-11 EP disclosed
US-4315009-A Antisecretory guanidine derivatives and pharmaceutical compositions containing them IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) 1982-02-09 US disclosed
EP-0003640-B1 ANTISECRETORY GUANIDINE DERIVATIVES, PROCESSES FOR THEIR MANUFACTURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1982-01-27 EP disclosed
EP-0003640-A2 Antisecretory guanidine derivatives, processes for their manufacture and pharmaceutical compositions containing them IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1979-08-22 EP disclosed
US-4036838-A Process for the production of nitro derivatives of aromatic compounds BAYER AKTIENGESELLSCHAFT (DT) 1977-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110957-A1 Process for the synthesis of an antiviral compound EIF2AK2, IRF3, RTF1 ALDH1A1 2288/4885CES2 1224/4885CES1 573/4885
US-20150237857-A1 ANTIBACTERIAL INHIBITORS MRPL21, Q6ZSR9, SPOUT1 ALDH1A1 3080/4885CES2 3098/4885CES1 3356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.